Abstract:Osteoporosis (OP) affects millions worldwide but currently cannot be cured. Suppressing the level of miR-214 in osteoclasts by the anti-miRNA oligonucleotide (AMO) anti-miR-214 reverses bone absorption and provides a potential treatment. Here we report a peptide-guided delivery strategy using red blood cell extracellular vesicles (RBCEVs) as the vehicle to realize osteoclast-targeted delivery of anti-miR-214. A bi-functional peptide, TBP-CP05, which binds to both the CD63 on RBCEVs and receptors on osteoclasts, acts as the guide. TBP-CP05 binds with RBCEVs through CP05, displays the TRAP-binding peptide (TBP) on the surface of EVs, and endows RBCEVs with osteoclast-targeting capability both in vitro and in vivo . Intravenous injection of the osteoclast-targeting RBCEVs (OT-RBCEVs) led to the enrichment of EVs in the bone skeleton, significant inhibition of the osteoclast activity, elevated osteoblast activity, and improved bone density in osteoporotic mice. Altogether, this work demonstrates efficient guidance of drug-loaded EVs to the targeted cells in vivo using bi-functional fusion peptides, and showcases that targeted delivery of anti-miR-214 by OT-RBCEVs may be a viable method for OP treatment. SIGNIFICANCE STATEMENT. Surface functionalization of EVs endows these nanovesicles cell-specific targeting property which guides the drug cargos to specific tissues and cells with higher accuracy, longer retention, and minimal off-target effects. Methods to functionalize EVs with minimal procedures are highly desired for clinical applications. Here we present a facile method using a bifunctional fusion peptide to guide RBCEVs to osteoclasts. A simple incubation of the bifunctional peptide and RBCEVs results in osteoclast-targeting RBCEVs (OT-RBCEVs) that effectively deliver anti-miR-214 to osteoclasts in vivo in a mouse model of osteoporosis, bringing a potential therapy to osteoporotic patients. This is, to our knowledge, the first report on peptide functionalization of RBCEVs and osteoclast-targeted delivery using RBCEVs.

A Bone-Resorption Surface-Targeting Nanoparticle to Deliver Anti-Mir214 for Osteoporosis Therapy.

Osteoblast-Targeting-Peptide Modified Nanoparticle for Sirna/Microrna Delivery

A Delivery System Specifically Approaching Bone Resorption Surfaces to Facilitate Therapeutic Modulation of Micrornas in Osteoclasts.

AAV-mediated Delivery of Osteoblast/osteoclast-Regulating Mirnas for Osteoporosis Therapy

AAV-mediated delivery of osteoblast/osteoclast-regulating miRNAs for osteoporosis therapy.

Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles

SDSSD Peptide Modified Polyvinylamine − A Novel Bone-Targeting RNA Delivery System

Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis

A Bone Targeting Nanoparticle Loaded Ogp to Restore Bone Homeostasis for Osteoporosis Therapy

Bone-Targeted Biomimetic Nanogels Re-Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis

Osteoclast-targeted delivery of anti-miRNA oligonucleotides by red blood cell extracellular vesicles

Bone-targeting PLGA derived lipid drug delivery system ameliorates bone loss in osteoporotic ovariectomized rats

Current Progress On Microrna-Based Gene Delivery In The Treatment Of Osteoporosis And Osteoporotic Fracture

Bone-Targeted Supramolecular Nanoagonist Assembled by Accurate Ratiometric Herbal-Derived Therapeutics for Osteoporosis Reversal.

Bone-Targeting HUVEC-Derived Exosomes Containing Mir-503-5p for Osteoporosis Therapy

Bone-targeting Cell Membrane-Engineered CaCO3-based Nanoparticles Restore Local Bone Homeostasis for Microenvironment-Responsive Osteoporosis Treatment

Bone-targeted Bioengineered Bacterial Extracellular Vesicles Delivering Sirna to Ameliorate Osteoporosis

Targeted Delivery of Anti-Osteoporosis Therapy: Bisphosphonate-modified Nanosystems and Composites

A Bone-Targeting Delivery Platform Based on Mesoporous Silica Loaded with Pir7472 for the Treatment of Osteoporosis

Construction of Multi‐Module RNA Nanoparticles Harboring miRNA, AIE, and CH6 Aptamer for Bone Targeting and Bone Anabolic Therapy